SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:lup.lub.lu.se:6cbcc0b5-dd85-4d11-84a0-c0a49105d7aa"
 

Search: onr:"swepub:oai:lup.lub.lu.se:6cbcc0b5-dd85-4d11-84a0-c0a49105d7aa" > Outcome in dediffer...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Hompland, IvarOslo university hospital (author)

Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy : Results from the EUROpean Bone Over 40 Sarcoma Study

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • Elsevier BV,2021
  • 9 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:6cbcc0b5-dd85-4d11-84a0-c0a49105d7aa
  • https://lup.lub.lu.se/record/6cbcc0b5-dd85-4d11-84a0-c0a49105d7aaURI
  • https://doi.org/10.1016/j.ejca.2021.04.017DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • Introduction: The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study. Materials and methods: The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models. Results: Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42–65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22–25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles. Conclusions: Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ferrari, StefanoRizzoli Orthopedic Institute (author)
  • Bielack, StefanKlinikum Stuttgart Olgahospital (author)
  • Palmerini, EmanuelaRizzoli Orthopedic Institute (author)
  • Hall, Kirsten S.Oslo university hospital (author)
  • Picci, PierroItalian Sarcoma Group (author)
  • Hecker-Nolting, StefanieKlinikum Stuttgart Olgahospital (author)
  • Donati, Davide M.Rizzoli Orthopedic Institute (author)
  • Blattmann, ClaudiaKlinikum Stuttgart Olgahospital (author)
  • Bjerkehagen, BodilOslo university hospital (author)
  • Staals, EricRizzoli Orthopedic Institute (author)
  • Kager, LeoMedical University of Vienna (author)
  • Gambarotti, MarcoRizzoli Orthopedic Institute (author)
  • Kühne, ThomasUniversity Children's Hospital, Basel (author)
  • Eriksson, MikaelLund University,Lunds universitet,Medicinsk onkologi,Sektion I,Institutionen för kliniska vetenskaper, Lund,Medicinska fakulteten,LUCC: Lunds universitets cancercentrum,Övriga starka forskningsmiljöer,Medical oncology,Section I,Department of Clinical Sciences, Lund,Faculty of Medicine,LUCC: Lund University Cancer Centre,Other Strong Research Environments,Skåne University Hospital(Swepub:lu)onk-mer (author)
  • Ferraresi, VirginiaNational Cancer Institute Regina Elena (author)
  • Kevric, MatthiasKlinikum Stuttgart Olgahospital (author)
  • Biagini, RobertoNational Cancer Institute Regina Elena (author)
  • Baumhoer, DanielUniversity Hospital Basel (author)
  • Brosjø, OtteKarolinska University Hospital (author)
  • Comandone, AlessandroOspedale Humanitas Gradenigo (author)
  • Schwarz, RudolfUniversity Medical Center Hamburg-Eppendorf (author)
  • Bertulli, RossellaIstituto Nazionale dei Tumori (author)
  • Kessler, TorstenUniversity Hospital Münster (author)
  • Hansson, LinaSahlgrenska University Hospital (author)
  • Apice, GaetanoIstituto Nazionale dei Tumori (author)
  • Heydrich, Björn N.University Medical Center Schleswig-Holstein (author)
  • Setola, ElisabettaRizzoli Orthopedic Institute (author)
  • Flörcken, AnneBerlin Institute of Health (BIH) (author)
  • Ruggieri, PietroUniversity of Padova (author)
  • Krasniqi, FatimeUniversity Hospital Basel (author)
  • Hofmann-Wackersreuther, GerdaKlinikum Nürnberg (author)
  • Casali, PaoloIstituto Nazionale dei Tumori (author)
  • Reichardt, PeterHELIOS Klinikum Berlin-Buch (author)
  • Smeland, SigbjørnOslo university hospital (author)
  • Oslo university hospitalRizzoli Orthopedic Institute (creator_code:org_t)

Related titles

  • In:European Journal of Cancer: Elsevier BV151, s. 150-1580959-8049

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view